Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • JN.1 Lineage
2024-2025 COVID-19 Vaccines Provide 79% Protection Against Critical Illness Despite Viral Evolution
Posted inInfectious Diseases news Public Health

2024-2025 COVID-19 Vaccines Provide 79% Protection Against Critical Illness Despite Viral Evolution

Posted by MedXY By MedXY 02/06/2026
A multicenter study reveals that 2024-2025 COVID-19 vaccines offer 40% protection against hospitalization and 79% against critical illness or death, maintaining efficacy against emerging JN.1 descendants like KP.3.1.1 and XEC.
Read More
  • Optimizing Value in Fibromyalgia Care: High-Dose Duloxetine and Pregabalin Outperform Amitriptyline in Lifetime Cost-Effectiveness Models
  • 2024-2025 COVID-19 Vaccines Provide 79% Protection Against Critical Illness Despite Viral Evolution
  • The 400 Percent Transit Penalty: How Travel Barriers Systemically Restrict Methadone Access
  • Post-Dobbs Abortion Bans Linked to Significant Rise in Postpartum Depression Among Low-Socioeconomic Populations
  • RSV-Related Hospitalization Linked to Surge in Acute Myocardial Infarction and Stroke Risk
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in